Dare Bioscience, Inc. (DARE) stock
DARENasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.45+0.02 (+4.90%)
Close on Nov 18, 2026Market cap $6.88MP/E –Yield –
Dare Bioscience free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Dare Bioscience's free cash flow for the twelve months ending Jun 30, 2026 was -$11.76M. For fiscal 2025 it was -$10.27M, down 309.6% from the year before. The highest annual figure on record is $4.90M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$10.27M | -309.6% |
| FY2024 | Dec 31, 2024 | $4.90M | – |
| FY2023 | Dec 31, 2023 | -$39.49M | – |
| FY2022 | Dec 31, 2022 | -$18.15M | – |
| FY2021 | Dec 31, 2021 | -$28.78M | – |
| FY2020 | Dec 31, 2020 | -$25.25M | – |
| FY2019 | Dec 31, 2019 | -$13.32M | – |
| FY2018 | Dec 31, 2018 | -$10.28M | – |
| FY2017 | Dec 31, 2017 | -$2.54M | – |
| FY2016 | Dec 31, 2016 | -$907.30K | – |
| FY2015 | Dec 31, 2015 | -$32.19M | – |
| FY2014 | Dec 31, 2014 | -$19.29M | – |
| FY2013 | Dec 31, 2013 | -$16.62M | – |
| FY2012 | Dec 31, 2012 | -$21.19M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.86M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.52M | – |
| Q4 FY2025 | Dec 31, 2025 | $1.24M | -73.9% |
| Q3 FY2025 | Sep 30, 2025 | -$616.84K | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.26M | -141.7% |
| Q1 FY2025 | Mar 31, 2025 | -$5.63M | – |
| Q4 FY2024 | Dec 31, 2024 | $4.74M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.64M | – |
| Q2 FY2024 | Jun 30, 2024 | $12.62M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.82M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.79M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.00M | -193.6% |
| Q2 FY2023 | Jun 30, 2023 | -$6.59M | – |
| Q1 FY2023 | Mar 31, 2023 | -$16.12M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.90M | – |
| Q3 FY2022 | Sep 30, 2022 | $8.55M | +554.4% |
| Q2 FY2022 | Jun 30, 2022 | -$8.45M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.35M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.92M | – |
| Q3 FY2021 | Sep 30, 2021 | $1.31M | – |
| Q2 FY2021 | Jun 30, 2021 | -$11.79M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.38M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.20M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.36M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.81M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.18M | -113.1% |
| Q4 FY2018 | Dec 31, 2018 | -$2.71M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.75M | – |
| Q4 FY2016 | Dec 31, 2016 | -$202.95K | – |
| Q3 FY2016 | Sep 30, 2016 | $24.27M | – |
See a number that looks wrong?